The company’s DNA-based platform is being developed to address key manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs).
NewBiologix’s $50 million series A was led by Recipharm A/S with additional funding from the company’s co-founders, Igor Fisch and Nicolas Mermod.
“As the number of gene and cell therapies in the clinic and market continues to grow, improved manufacturing solutions for viral vectors are needed,” said NewBiologix co-founder and CEO, Igor Fisch, who brings more than 20 years’ experience in biotech and cell line development to the new entity.
“Our mission is to help biopharmaceutical companies treat some of the most devastating diseases by providing them with innovative technologies and solutions to boost the production and efficacy of viral vectors, rapidly and more cost effectively.”
NewBiologix is currently focused on recombinant adeno-associated virus (rAAV) vectors, the preferred delivery vehicle for gene therapies.
The company’s technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines.
These cell lines will be engineered to be readily adaptable to meet the viral vector demands and requirements over a full range of therapeutic indications to help partners address rare, chronic, and currently incurable diseases.
Cell lines engineered with NewBiologix’s innovative platform will allow for more stable rAAV production, higher quality and predictable expression levels, less empty capsids, and better batch-to-batch reproducibility of production.
Full Link ( Here )
